Systematic review of the efficacy and safety of lenvatinib in various solid tumors

References

• Hao Z, Wang P. Lenvatinib in management of solid tumors. Oncologist. 2020;25(2):e302–e310. doi: 10.1634/theoncologist.2019-0407.
   PubMed Web of Science ®Google Scholar
• Okamoto K, Kodama K, Takase K, et al. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 2013;340(1):97–103. doi: 10.1016/j.canlet.2013.07.007.
   PubMed Web of Science ®Google Scholar
• Tohyama O, Matsui J, Kodama K, et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014;2014:638747–638713. doi: 10.1155/2014/638747.
   PubMedGoogle Scholar
• Hiraoka A, Kumada T, Kariyama K, Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan), et al. Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: multicenter analysis. Hepatol Res. 2019;49(1):111–117. doi: 10.1111/hepr.13243.
   PubMed Web of Science ®Google Scholar
• Arora S, Balasubramaniam S, Zhang W, et al. FDA approval summary: Pembrolizumab plus lenvatinib for endometrial carcinoma, a collaborative international review under project orbis. Clin Cancer Res. 2020;26(19):5062–5067. doi: 10.1158/1078-0432.CCR-19-3979.
   PubMed Web of Science ®Google Scholar
• Nair A, Reece K, Donoghue MB, et al. FDA supplemental approval summary: lenvatinib for the treatment of unresectable hepatocellular carcinoma. Oncologist. 2021;26(3):e484–e491. doi: 10.1002/onco.13566.
   PubMed Web of Science ®Google Scholar
• Lu M, Zhang X, Gao X, et al. Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in cancer. Pharmacol Res. 2021;174:105829. doi: 10.1016/j.phrs.2021.105829.
   PubMed Web of Science ®Google Scholar
• Nagai H, Mukozu T, Kobayashi K, et al. Lenvatinib might induce activation of host immunity in patients with hepatocellular carcinoma. Oncology. 2023;101(1):32–40. doi: 10.1159/000527306.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Liu H, Wang H, et al. Lenvatinib promotes antitumor immunity by enhancing the tumor infiltration and activation of NK cells. Am J Cancer Res. 2019;9(7):1382–1395.
   PubMed Web of Science ®Google Scholar
• Yamauchi M, Ono A, Amioka K, et al. Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma. Commun Med (Lond). 2023;3(1):152. doi: 10.1038/s43856-023-00390-x.
   PubMedGoogle Scholar
• Yang J, Guo Z, Song M, et al. Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFRβ complex in hepatocellular carcinoma. Front Immunol. 2023;14:1212577. doi: 10.3389/fimmu.2023.1212577.
   PubMed Web of Science ®Google Scholar
• Gan Y, Li L, Zhang L, et al. Association between shift work and risk of prostate cancer: a systematic review and meta-analysis of observational studies. Carcinogenesis. 2018;39(2):87–97. doi: 10.1093/carcin/bgx129.
   PubMed Web of Science ®Google Scholar
• Makker V, Colombo N, Casado Herráez A, Study 309–KEYNOTE-775 Investigators, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386(5):437–448. doi: 10.1056/NEJMoa2108330.
   PubMed Web of Science ®Google Scholar
• Yonemori K, Yunokawa M, Ushijima K, et al. Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: results from study 309/KEYNOTE-775. Cancer Sci. 2022;113(10):3489–3497. doi: 10.1111/cas.15436.
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–630. doi: 10.1056/NEJMoa1406470.
   PubMed Web of Science ®Google Scholar
• Zheng X, Xu Z, Ji Q, et al. A randomized, phase III study of lenvatinib in Chinese patients with radioiodine-refractory differentiated thyroid cancer. Clin Cancer Res. 2021;27(20):5502–5509. doi: 10.1158/1078-0432.CCR-21-0761.
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi: 10.1016/S0140-6736(18)30207-1.
   PubMed Web of Science ®Google Scholar
• Ding X, Sun W, Li W, et al. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: a prospective randomized study. Cancer. 2021;127(20):3782–3793. doi: 10.1002/cncr.33677.
   PubMed Web of Science ®Google Scholar
• Yamashita T, Kudo M, Ikeda K, et al. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol. 2020;55(1):113–122. doi: 10.1007/s00535-019-01642-1.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–1482. doi: 10.1016/S1470-2045(15)00290-9. Epub 2015 Oct 22. Erratum in: Lancet Oncol. 2016 Jul;17 (7):e270. Erratum in: Lancet Oncol. 2018 Oct;19(10):e509.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Eto M, Motzer R, et al. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet Oncol. 2023;24(3):228–238. doi: 10.1016/S1470-2045(23)00049-9. Erratum in: Lancet Oncol. 2023 Apr;24(4):e146.
   PubMed Web of Science ®Google Scholar
• Motzer R, Alekseev B, Rha SY, CLEAR Trial Investigators, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289–1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13.
   PubMed Web of Science ®Google Scholar
• Eto M, Takagi T, Kimura G, et al. Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study. Cancer Med. 2023;12(6):6902–6912. doi: 10.1002/cam4.5483. Epub 2022 Dec 1.
   PubMed Web of Science ®Google Scholar
• Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10(2):116–129. doi: 10.1038/nrc2780.
   PubMed Web of Science ®Google Scholar
• Lee SH, Jeong D, Han YS, et al. Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis. Ann Surg Treat Res. 2015;89(1):1–8. doi: 10.4174/astr.2015.89.1.1.
   PubMed Web of Science ®Google Scholar
• Matsuki M, Hoshi T, Yamamoto Y, et al. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med. 2018;7(6):2641–2653. doi: 10.1002/cam4.1517.
   PubMed Web of Science ®Google Scholar
• Hoshi T, Watanabe Miyano S, Watanabe H, et al. Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK Cascades. Biochem Biophys Res Commun. 2019;513(1):1–7. doi: 10.1016/j.bbrc.2019.02.015.
   PubMed Web of Science ®Google Scholar
• Cabanillas ME, Schlumberger M, Jarzab B, et al. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment. Cancer. 2015;121(16):2749–2756. doi: 10.1002/cncr.29395.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Kudo M, Kawazoe S, et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol. 2017;52(4):512–519. doi: 10.1007/s00535-016-1263-4.
   PubMed Web of Science ®Google Scholar
• Kato Y, Tabata K, Kimura T, et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One. 2019;14(2):e0212513. doi: 10.1371/journal.pone.0212513.
   PubMed Web of Science ®Google Scholar
• Lee CH, Shah AY, Rasco D, et al. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncol. 2021;22(7):946–958. doi: 10.1016/S1470-2045(21)00241-2.
   PubMed Web of Science ®Google Scholar
• Vergote I, Powell MA, Teneriello MG, et al. Second-line lenvatinib in patients with recurrent endometrial cancer. Gynecol Oncol. 2020;156(3):575–582. doi: 10.1016/j.ygyno.2019.12.039.
   PubMed Web of Science ®Google Scholar
• Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156(2):477–491.e1. doi: 10.1053/j.gastro.2018.08.065.
   PubMed Web of Science ®Google Scholar
• Hirooka M, Ochi H, Hiraoka A, et al. Destructive thyroiditis induced by lenvatinib in three patients with hepatocellular carcinoma. Intern Med. 2019;58(6):791–795. doi: 10.2169/internalmedicine.1874-18.
   PubMed Web of Science ®Google Scholar
• Hyogo Y, Kiyota N, Otsuki N, et al. Thrombotic microangiopathy with severe proteinuria induced by lenvatinib for radioactive iodine-refractory papillary thyroid carcinoma. Case Rep Oncol. 2018;11(3):735–741. doi: 10.1159/000494080.
   PubMed Web of Science ®Google Scholar
• Furuto Y, Hashimoto H, Namikawa A, et al. Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report. BMC Nephrol. 2018;19(1):273. doi: 10.1186/s12882-018-1074-3.
   PubMedGoogle Scholar